Singapore - English - HSA (Health Sciences Authority)

glaxosmithkline pte ltd - influenza virus (nh) a/california/7/2009 (h1n1)pdm09 - like strain - injection - 15 mcg haemagglutinin/0.5 ml

Singapore - English - HSA (Health Sciences Authority)

glaxosmithkline pte ltd - amoxycillin trihydrate 459.17mg/5ml eqv amoxycillin; potassium clavulanate 67.9mg/5ml eqv clavulanic acid - powder, for suspension - 400 mg/5 ml - amoxycillin trihydrate 459.17mg/5ml eqv amoxycillin 400 mg/5 ml; potassium clavulanate 67.9mg/5ml eqv clavulanic acid 57 mg/5 ml

Israel - English - Ministry of Health

glaxo smith kline (israel) ltd - amoxicillin as trihydrate; clavulanic acid as potassium salt - powder for suspension - amoxicillin as trihydrate 600 mg / 5 ml; clavulanic acid as potassium salt 42.9 mg / 5 ml - amoxicillin and enzyme inhibitor - augmentin es is indicated for the treatment of acute otitis media in children aged at least 3 months and less than 40 kg body weight, caused or thought likely to be caused by penicillin-resistant streptococcus pneumoniae:consideration should be given to official guidance on the appropriate use of antibacterial agents.

Israel - English - Ministry of Health

glaxo smith kline (israel) ltd - amoxicillin as trihydrate; clavulanic acid as potassium salt - powder for suspension - amoxicillin as trihydrate 600 mg / 5 ml; clavulanic acid as potassium salt 42.9 mg / 5 ml - amoxicillin and enzyme inhibitor - augmentin es is indicated for the treatment of acute otitis media in children aged at least 3 months and less than 40 kg body weight, caused or thought likely to be caused by penicillin-resistant streptococcus pneumoniae:consideration should be given to official guidance on the appropriate use of antibacterial agents.

Australia - English - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - influenza virus haemagglutinin -

Australia - English - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - aciclovir -

European Union - English - EMA (European Medicines Agency)

smithkline beecham ltd - rosiglitazone, glimepiride - diabetes mellitus, type 2 - drugs used in diabetes - avaglim is indicated in the treatment of type 2 diabetes mellitus patients who are unable to achieve sufficient glycaemic control on optimal dosage of sulphonylurea monotherapy, and for whom metformin is inappropriate because of contraindication or intolerance.

European Union - English - EMA (European Medicines Agency)

smithkline beecham plc - rosiglitazone, metformin hydrochloride - diabetes mellitus, type 2 - drugs used in diabetes - avandamet is indicated in the treatment of type 2 diabetes mellitus patients, particularly overweight patients:who are unable to achieve sufficient glycaemic control at their maximally tolerated dose of oral metformin alone.in triple oral therapy with sulphonylurea in patients with insufficient glycaemic control despite dual oral therapy with their maximally tolerated dose of metformin and a sulphonylurea (see section 4.4).

European Union - English - EMA (European Medicines Agency)

smithkline beecham plc - rosiglitazone - diabetes mellitus, type 2 - drugs used in diabetes - rosiglitazone is indicated in the treatment of type 2 diabetes mellitus:as monotherapy-in patients (particularly overweight patients) inadequately controlled by diet and exercise for whom metformin is inappropriate because of contraindications or intoleranceas dual oral therapy in combination with-metformin, in patients (particularly overweight patients) with insufficient glycaemic control despite maximal tolerated dose of monotherapy with metformin-a sulphonylurea, only in patients who show intolerance to metformin or for whom metformin is contraindicated, with insufficient glycaemic control despite monotherapy with a sulphonylureaas triple oral therapy in combination with-metformin and a sulphonylurea, in patients (particularly overweight patients) with insufficient glycaemic control despite dual oral therapy (see section 4.4).

Australia - English - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - tretinoin, quantity: 0.5 mg/g - cream - excipient ingredients: propylene glycol; purified water; peg-40 stearate; white soft paraffin; propyl hydroxybenzoate; disodium edetate; stearyl alcohol; stearic acid; methyl hydroxybenzoate; butylated hydroxytoluene; isopropyl palmitate; butylated hydroxyanisole - indicated for use in the treatment of acne vulgaris, in particular forms where comedones, papules and pustules predominate.